Agoracom: Small Cap Investment - Zenith Epigenetics - April 29, 2021: Triple Negative Breast Cancer Drug Development Digital Summit 2021

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

April 29, 2021: Triple Negative Breast Cancer Drug Development Digital Summit 2021

posted on Apr 28, 2021 11:43AM

April 29, 2021: Triple Negative Breast Cancer Drug Development Digital Summit 2021

On April 29, 2021, Dr. Eric Campeau will be presenting at the Triple Negative Breast Cancer Drug Development Digital Summit 2021: "Phase 1b/2 Combination Study of the BET Inhibitor ZEN-3694 with the PARP Inhibitor Talazoparib for the Treatment of TNBC Patients without gBRCA1/2 Mutations." More info can be found HERE

8 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply